Global Vasomotor Menopausal Symptoms (VMS) Treatment Market – Industry Trends and Forecast to 2031

Análisis y tamaño del mercado de tratamiento de los síntomas vasomotores de la menopausia (VMS)

El mercado del tratamiento de los síntomas vasomotores de la menopausia (SVM) está impulsado por la creciente prevalencia de los síntomas menopáusicos entre las mujeres de todo el mundo. La terapia hormonal, en particular la terapia con estrógenos, sigue siendo un tratamiento ampliamente utilizado y eficaz para los SVM, aunque las preocupaciones sobre su seguridad han llevado a una mayor demanda de terapias alternativas. Los tratamientos no hormonales, como los inhibidores selectivos de la recaptación de serotonina (ISRS) y los inhibidores de la recaptación de serotonina y noradrenalina (IRSN), están ganando popularidad debido a sus perfiles de eficacia y seguridad. La creciente conciencia sobre los síntomas de la menopausia y su impacto en la calidad de vida está impulsando a las mujeres a buscar tratamiento, lo que impulsa aún más el crecimiento del mercado.

El tamaño del mercado global de tratamiento de los síntomas vasomotores de la menopausia (VMS) se valoró en USD 17,75 mil millones en 2023 y se proyecta que alcance los USD 28,72 mil millones para 2031, con una CAGR del 6,20% durante el período de pronóstico de 2024 a 2031. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado       

Market Definition

Vasomotor Menopausal Symptoms (VMS), also known as hot flashes or night sweats, are common symptoms experienced by women during menopause. These symptoms are caused by hormonal changes, specifically the decline in estrogen levels, which can impact the body's ability to regulate temperature. VMS treatment aims to alleviate these symptoms and improve the quality of life for women experiencing them. Treatment options include hormone therapy (estrogen therapy), which can effectively reduce the frequency and severity of VMS, and non-hormonal treatments such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and lifestyle changes.

Vasomotor Menopausal Symptoms (VMS) Treatment Market Dynamics

Drivers

• Increasing Aging Population   

With women living longer, the number of women experiencing menopause and its associated symptoms, including VMS, is expected to rise. As women age, the decline in estrogen levels leads to symptoms such as hot flashes and night sweats. This demographic trend creates a growing demand for effective VMS treatment options, driving market growth.   

• Technological Advancements in Treatment Options   

Ongoing technological advancements include the development of new drug formulations and delivery methods that offer more effective and convenient treatment options for women experiencing VMS. Transdermal patches and gels, offer a non-oral method for hormone therapy, providing women with a variety of options for managing their symptoms. In addition, novel drug formulations and delivery methods aim to improve treatment efficacy and patient compliance, further boosting market growth.

Opportunities

• Rising Awareness and Treatment-seeking Behavior    

Women are becoming more informed about the impact of VMS on their quality of life and are actively seeking effective treatment options to manage these symptoms. This is supported by a growing body of information available through various channels, including healthcare providers, online resources, and community outreach programs. With growing awareness, an increasing number of women are expected to seek treatment for VMS, thereby expanding the market for VMS treatment options.

• Development of Novel Treatment Options   

The development of novel treatment options for Vasomotor Menopausal Symptoms (VMS), such as new drug formulations and non-hormonal therapies, has the potential to meet market demands by providing women experiencing VMS with more effective and safer options. For instance, new drug formulations may provide improved symptom relief with fewer side effects, while non-hormonal therapies offer alternatives for women who cannot or prefer not to use hormone-based treatments. These advancements in treatment options are likely to drive market expansion as they provide more choices for patients and healthcare providers.

Restraints/Challenges

• Safety Concerns Associated with Hormone Therapy   

Safety concerns regarding the long-term use of hormone therapy, particularly the risk of cardiovascular events and cancer, have led to a decline in the use of hormone therapy and an increased demand for alternative treatments. Healthcare providers and patients are increasingly cautious about the risks associated with hormone therapy, leading to a shift towards non-hormonal treatment options. As a result, market growth for hormone therapy products is being impacted by these safety concerns.    

• Availability of Non-pharmacological Alternatives  

The availability of non-pharmacological alternatives, such as lifestyle modifications and alternative therapies, is often preferred by women seeking natural or holistic approaches to managing VMS, as they may perceive them to be safer or more in line with their personal beliefs and values. Non-pharmacological alternatives include dietary changes, exercise, stress management techniques, and acupuncture, among others. The availability and acceptance of these alternatives by women experiencing VMS contribute to the limited growth of the pharmacological treatment market, as some women may choose these options over traditional medication.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Vasomotor menopausal symptoms (VMS) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• En abril de 2024, Knight Therapeutics Inc. anunció el lanzamiento de Imvexxy y Bijuva en Canadá. Imvexxy está indicado para el tratamiento de la dispareunia posmenopáusica moderada a severa, un síntoma de atrofia vulvar y vaginal (AVV). Es el único producto de su clase terapéutica que ofrece dosis de 4 mcg y 10 mcg. BIJUVA es la primera combinación aprobada por Health Canada de 1 mg de estradiol y 100 mg de progesterona micronizada en una sola cápsula oral diaria. Está indicado para el tratamiento de los síntomas vasomotores (VMS) moderados a severos asociados con la menopausia en mujeres con útero intacto.
• En mayo de 2023, VEOZAH (fezolinetant) de Astellas Pharma Inc. se convirtió en el primer antagonista no hormonal del receptor de neuroquinina 3 (NK3) en recibir la aprobación de la FDA. VEOZAH está indicado para el tratamiento de los síntomas vasomotores (VMS) asociados con la menopausia.      
• En marzo de 2022, Amyris, Inc. adquirió MenoLabs, LLC, una empresa especializada en el tratamiento de los síntomas de la menopausia y en la realización de investigaciones en este campo. A través de esta adquisición, Amyris, Inc. amplió su cartera de productos para el tratamiento de la menopausia.

Alcance del mercado del tratamiento de los síntomas vasomotores de la menopausia (VMS)

El mercado está segmentado en función de la clase de fármaco, la vía de administración, los usuarios finales y el canal de distribución. El crecimiento entre estos segmentos le ayudará a analizar los segmentos de crecimiento reducido de las industrias y brindará a los usuarios una valiosa descripción general del mercado y conocimientos del mercado para ayudarlos a tomar decisiones estratégicas para identificar las principales aplicaciones del mercado.

Clase de droga

• Antidepresivos
• Fluoxetina
• Paroxetina
• Sertralina
• Terapia hormonal
• Anticonvulsivo
• Fenitoína
• Fenobarbital
• Otros

Vía de administración

• Oral
• Parenteral
• Otros

Usuarios finales

• Hospitales
• Clínicas de especialidades
• Cuidado domiciliario
• Otros

Canal de distribución

• Farmacia hospitalaria
• Farmacia minorista
• Farmacia en línea
• Otros

Análisis y perspectivas regionales del mercado de tratamiento de los síntomas vasomotores de la menopausia (VMS)

Se analiza el mercado y se proporcionan información y tendencias del tamaño del mercado por país, clase de medicamento, vía de administración, usuarios finales y canal de distribución como se mencionó anteriormente.

Los países cubiertos en el mercado son EE. UU., Canadá, México, Alemania, Francia, Reino Unido, Países Bajos, Suiza, Bélgica, Rusia, Italia, España, Turquía, resto de Europa, China, Japón, India, Corea del Sur, Singapur, Malasia, Australia, Tailandia, Indonesia, Filipinas, resto de Asia-Pacífico, Arabia Saudita, Emiratos Árabes Unidos, Sudáfrica, Egipto, Israel, resto de Medio Oriente y África, Brasil, Argentina y resto de Sudamérica.

Se espera que América del Norte domine el mercado debido a su infraestructura de atención médica avanzada y completa. La región cuenta con instalaciones y servicios de atención médica bien establecidos, lo que garantiza un amplio acceso a las tecnologías de automatización médica. Además, América del Norte muestra altos niveles de conocimiento de los consumidores con respecto a los avances en el cuidado de la salud, lo que genera un mercado más receptivo a las soluciones de automatización médica. La presencia de actores clave del mercado y las innovaciones tecnológicas en curso consolidan aún más el crecimiento del mercado en la región.

Asia-Pacific is expected to witness significant growth during the forecast period due to a growing patient pool, increasing investments in the healthcare sector, and rising government support. Traditional Chinese medicine is highly instrumental in managing menopausal symptoms and accelerating menopause treatment market growth.  Women have an array of choices for controlling menopausal symptoms because of the coexistence of modern therapeutic approaches and traditional Japanese medicine, such as Kampo therapy. These factors intensify the adoption of menopause treatments in Japan.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for vasomotor menopausal symptoms (VMS) treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Vasomotor Menopausal Symptoms (VMS) Treatment Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the market are:

• Zhejiang Huahai Pharmaceutical Co., Ltd (China)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Pfizer Inc (U.S.)
• Hikma Pharmaceutical PLC (U.K)
• Amneal Pharmaceuticals LLC. (U.S.)
• Alembic Pharmaceuticals Limited (India)
• Zydus Group (India)
• Dr. Reddy’s Laboratories Ltd (India)
• Abbvie, Inc (U.S.)
• Sun Pharmaceutical Industries Ltd (India)
• Apotex Inc (Canada)
• Aurobindo Pharma (India)
• Endo Pharmaceuticals plc (Ireland)
• Lupin (India)
• Novartis AG (Switzerland)
• WOCKHARDT (India)

SKU-52905